Related Experiment Video

Updated: Jun 24, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Development of cell-cycle inhibitors for cancer therapy

M A Dickson1, G K Schwartz

  • 1Department of Medicine, Division of Solid Tumor Oncology, Melanoma and Sarcoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.

Current Oncology (Toronto, Ont.)
|April 17, 2009
PubMed

Insights

Cyclin-dependent kinases (CDKs) are key cell cycle regulators and promising cancer drug targets. CDK inhibitors show potential, especially in combination therapies for hematologic malignancies, with dose and schedule being critical for efficacy.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • The cell cycle controls cell growth and proliferation, involving cyclin-dependent kinases (CDKs) and cyclins.
  • Aberrant CDK expression in cancer makes them attractive therapeutic targets, as inhibition can induce cell death and block transcription.

Purpose of the Study:

  • To review the clinical progress and therapeutic potential of CDK inhibitors in cancer treatment.
  • To evaluate the safety, efficacy, and optimal dosing strategies for various CDK-targeting drugs.

Main Methods:

  • Review of clinical trial data (Phase I and II) for several CDK inhibitors.
  • Analysis of pharmacodynamic studies to understand drug effects and scheduling.
  • Examination of single-agent versus combination therapy outcomes in solid tumors and hematologic malignancies.

Main Results:

  • CDK inhibitors have demonstrated safety in Phase I trials.
  • Limited single-agent activity observed in solid tumors, but promising results in combination with chemotherapy.
  • Encouraging single-agent and combination activity reported in hematologic malignancies.
  • Pharmacodynamic studies highlight the critical importance of drug dose and schedule.

Conclusions:

  • CDK inhibitors represent a viable therapeutic strategy in oncology.
  • Combination therapies and tailored dosing schedules are crucial for maximizing the efficacy of CDK inhibitors, particularly in hematologic cancers.
Keywords:
Cell cyclecyclin-dependent kinasescyclinsphase i clinical trialsphase ii clinical trials

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry11:23

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry

Published on: May 22, 2012

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...